Global Tumor Ablation Research Industry to Undergo Major Transformation in Near Future

Recent developments in the Global Tumor Ablation Procedure Industry:

# In October 2015, AngioDynamics, Inc. launched its NanoKnife Ablation system in South Korea after receiving regulatory approval by Ministry of Food and Drug Safety (South Korea). This helped AngioDynamics expand its product portfolio for tumor ablation market.

# In July 2016, Boston Scientific Corporation acquired the Cosman Medical Inc. (U.S.) at an undisclosed value. Cosman Medical is a leading manufacturer of radiofrequency ablation devices. This acquisition helped Boston Scientific to strengthen its technological capabilities and to expand its product sales and distribution network in the global tumor ablation market.

# In May 2016, Galil Medical Inc. was acquired by the BTG plc group (a part of BTG International Ltd, U.K.); for a value of USD 110.0 million. BTG International is prominent manufacturer of cryoablation products and possesses strong product distribution network across Europe. The acquisition helped Galil Medical to strengthen its technological capabilities and to expand its distribution network in global tumor ablation market.

# In april 2016, Medtronic plc launched Barrx 360 Express radiofrequency ablation (RFA) balloon catheter; for the treatment of Barrett’s esophagus. It helped the company to provide technologically advanced product to its customers in tumor ablation market.

Major Growth Influencing Factors:

Key factors such growing geriatric population, continuous expansion in population base of cancer patients across the globe, and ongoing technological advancements in the field of tumor ablation product are the major factors driving the growth of the tumor ablation market across the globe.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=142550258

Expected Growth Scenario Across Geographies:

North America is expected to account for the largest share of the market during the forecast period

North America is one of the major revenue-generating regions in the global tumor ablation market. The large share of this regional segment can mainly be attributed to early introduction of tumor ablation technologies in the region, continuous technological advancements occurring in the field of tumor ablation catheters, and growing private-public investments to develop innovative tumor ablation technologies (coupled with the growing public awareness related to the benefits of tumor ablation).

Key questions addressed in this Report:

# What are the growth opportunities related to tumor ablation across major regions in the future?
# Emerging countries have immense opportunities for the growth and adoption of tumor ablation products. Will this scenario continue in the next five years?
# Where will all the advancements in products offered by various companies take the industry in the mid- to long-term?
# What are the new trends and advancements in the tumor ablation market?

Applications of the Technology:

On the basis of application, the market is segmented into liver cancer, lung cancer, kidney cancer, bone metastasis, other applications. The liver cancer segment is expected to account for the largest share of the tumor ablation market in 2016.

Factors such as high adoption rate of ablation techniques among healthcare professionals for the treatment of liver carcinoma, significant medical reimbursements available in the US and ~53% reimbursement for liver cancer treatment provided by Medicare, larger proportion of global population exposed to various risk factors for liver cancer as compared to that for other cancer types, and significant life expectancy in patients after liver tumor ablation drive the growth of this segment.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=142550258

Global Leaders:

The key players present in the global tumor ablation market focus on various strategies such as product approvals, launches, and enhancements; strategic acquisitions; partnerships, agreements, and collaborations; and geographic expansions in order to increase their shares in the global tumor ablation market.

During 2013-2016, product approvals, launches, and enhancements; and acquisitions were the key strategies adopted by major industry players, including AngioDynamics, Inc. (U.S.), Boston Scientific Corporation (U.S.), Galil Medical (Israel), EDAP TMS S.A. (France), HealthTronics, Inc. (U.S.), Medtronic plc (Ireland), and SonaCare Medical LLC (U.S.).

Other strategies adopted by many prominent players include fund raising from private/government sources to enhance their research & development capabilities; initiatives to increase awareness about tumor ablation; and geographic expansions.

Product Development and Acquisition - Key Strategies Adopted by Leading Players to Enhance Growth in the Global Tumor Ablation Market

Key Market Drivers:

# Growing Geriatric Population Across the World

# Increasing Population Base for Cancer Patients

# Technological Advancements in Ablation Devices

# Sprouting Number of Hospitals, Surgical, and Ablation Centers

Key Market Restraints:

# Cost Containment Measures Taken By Various Governments

# Ongoing Healthcare Reforms in the U.S.

Key Market Opportunities:

# Growth Potential Offered By Emerging Markets

# Growing Awareness About Ablation Procedures Over Conventional Therapeutic and Surgical Procedures

Download the PDF Brochure@

https://www.marketsandmarkets.com/pdfdownload.asp?id=142550258

The key players present in the global tumor ablation market focus on various strategies such as product approvals, launches, and enhancements; strategic acquisitions; partnerships, agreements, and collaborations; and geographic expansions in order to increase their shares in the global tumor ablation market.

During 2013-2016, product approvals, launches, and enhancements; and acquisitions were the key strategies adopted by major industry players, including AngioDynamics, Inc. (U.S.), Boston Scientific Corporation (U.S.), Galil Medical (Israel), EDAP TMS S.A. (France), HealthTronics, Inc. (U.S.), Medtronic plc (Ireland), and SonaCare Medical LLC (U.S.). Other strategies adopted by many prominent players include fund raising from private/government sources to enhance their research & development capabilities; initiatives to increase awareness about tumor ablation; and geographic expansions.

As of 2015, Medtronic plc (Ireland) held the leading position in the tumor ablation market owing to its robust product portfolio and its strong geographic presence across major markets (such as the U.S., Europe, China, Japan, Brazil, and India). The company primarily focuses on strategic acquisitions and development of technologically advanced tumor ablation systems as its key growth strategies to sustain its leadership position in the market. In line with this strategy, during 2013-2016, the company launched several tumor ablation products such as OsteoCool RF Ablation System (2016) and Barrx 360 Express radiofrequency ablation (RFA) balloon catheter (2016).

The company also adopted geographic expansion as another key growth strategy to strengthen its sales and product distribution capabilities. In line with this, Medtronic set up the Asia-Pacific regional headquarters in Singapore Singapore Health Services (SingHealth) in May 2016; SingHealth will help streamline and expand the company’s regional operations across 80 locations in Asia-Pacific.

AngioDynamics, Inc. (U.S.) held the second position in the tumor ablation market in 2015. The company has a strong product portfolio in the global tumor ablation market, including products such as Acculis MTA system, NanoKnife system, StarBurst RFA system, and UniBlate RFA electrodes. The company pursued strategic acquisitions and expansions of existing product portfolio (as well as pipeline development) as its key growth strategies. During 2013-2016, AngioDynamics acquired Microsulis Medical Ltd. (U.S.) and Navilyst Medical Inc. (U.S.); these acquisitions helped the company strengthen its market position and geographic presence. Additionally, in August 2016, AngioDynamics reported excellent clinical results with its Acculis Microwave Tissue Ablation System during cancer treatment studies (lung tumor, bone tumor, and renal tumor). This helped company to further strengthen the pipeline development for microwave ablation products.

Read the Detailed Article on "Tumor Ablation Market - Global Forecast 2021", Here..!